Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Summary

The purpose of this study is to assess the impact of an individual physical activity intervention (IPAI) on health-related quality of life (HRQoL) in participants with first line or relapsed chronic lymphocytic leukemia (CLL) initiating ibrutinib in a routine clinical practice setting. HRQoL will be measured using functional assessment of cancer therapy - general scale (FACT-G).

Eligibility

Inclusion Criteria:

* Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
* Participants agreed to follow the individual physical activity intervention (IPAI)
* Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
* Participants with Internet access at home and email address
* Participants agreed to wear a connected watch 24 hours a day for all the duration of the study

Exclusion Criteria:

* Pregnant participants or planning to become pregnant while enrolled in this study
* Participants with inability or deemed unsafe to practice physical activity
* Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
* Participants who are currently involved in an interventional study
* Participants with probable difficulties in using the digital tool autonomously

Conditions2

Interventions1

Related trials

• A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) — Jeanette Lundin
• A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma — Guangzhou Lupeng Pharmaceutical Company LTD.
• CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma — Christian Schmidt, MD
• Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma — Canadian Cancer Trials Group
• Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL — Ascentage Pharma Group Inc.
• Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) — Paolo Ghia
• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) — Merck Sharp & Dohme LLC
• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) — Curis, Inc.

Browse More Trials